18 October 2023 - NICE has published final evidence based recommendations on the use of rimegepant sulphate (Vydura) for the treatment of adults with acute migraine.

Rimegepant sulphate is recommended as an option for the treatment of adults with acute migraine with or without aura, only if for previous migraines:

• At least two serotonin (5-HT1) receptor agonists were tried and they did not work well enough or
• The use of two serotonin (5-HT1) receptor agonists were contra-indicated or not tolerated, and non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol were tried but did not work well enough

Read NICE technology appraisal guidance